Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micromet Inc (MITI) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (40)	8/3/2006 4:49:47 PM
From: keokalani'nui	Respond to of 196

I only have it, and only a little, because it was cheap and they have some novel ideas (bites), and I felt the reverse cross-atlantic IPO would allow for apprecitation with time. Ep-cam, as as target, had excited me about as much as mucin, ie, not at all. So far nothing has worked in miti's favor, and the first bite had low therapeutic window. I never did the work I would on a full position, so sorry for not being more help. Probably will take a loss this fall and come back in later. Maybe I'll learn eventually....

To: tuck who wrote (40)	8/3/2006 6:02:43 PM
From: dr.praveen	Read Replies (1) \| Respond to of 196

Hi Tuck, I used to have a large position in Micromet and made more than a double during the reverse merger. I am not enthusiastic about MT201. Open trial, small no's, subset efficacy? P value doesn't seem convincing. I think they only went for other indications for MT201 due to the milestones they will get from Serono. Antibody D93 is from cancervax.I have a very small position in them now and I am only there for the Bite compounds(bispecific single chain antibodies) and I am looking for further data from MT103 inorder to increase my position. Best, Praveen